All In Biotech

Drug Trial Radar · NCT03523728

A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients

Multicenter, Randomized, Double-blind, Placebo-controlled Two Stage Study to Characterize the Efficacy, Safety, Tolerability and Pharmacokinetics of GZ/SAR402671 in Patients at Risk of Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Last checked: Nov 19, 2026Latest source record: Feb 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 478 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

478

Actual

Start

Oct 4, 2018

Primary completion

Aug 3, 2021

Study completion Aug 3, 2021

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
May 14, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To determine the effect of venglustat on the rate of total kidney volume (TKV) growth (Stage 1) and estimated glomerular filtration rate (eGFR) decline in participants at risk of rapidly progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD) (Stage 2). Secondary Objectives: * To determine the effect of venglustat on the rate of renal function decline (Stage 1) and on the rate of TKV growth (Stage 2). * To evaluate the pharmacokinetics (PK) of venglustat in ADPKD participants (Stages 1 and 2). * To determine the effect of venglustat on pain and fatigue, based on participant reported diary (Stages 1 and 2). * Safety/tolerability objectives: * To characterize the safety profile of venglustat (Stages 1 and 2). * To evaluate the effect of venglustat on mood using Beck Depression Inventory II (BDI-II) (Stages 1 and 2). * To evaluate the effect of venglustat on the lens by ophthalmological examination (Stages 1 and 2).

Conditions

  • Polycystic Kidney, Autosomal Dominant

Interventions

  • VenglustatDrug

    Pharmaceutical form: capsule; Route of administration: oral

  • PlaceboDrug

    Pharmaceutical form: capsule; Route of administration: oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Slope of Change in Total Kidney Volume (TKV) From Baseline to Month 18: Stage 1Time frame: From Baseline to Month 18
  2. Annualized Rate of Change in Estimated Glomerular Filtration Rate (eGFR) (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) From Baseline to Month 24: Combined Stage 1 and Stage 2Time frame: From Baseline to Month 24

Locations

95 sites in 23 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 8400002

    Birmingham, Alabama

  • Investigational Site Number 8400017

    Los Angeles, California

  • Investigational Site Number 8400001

    San Francisco, California

  • Investigational Site Number 8400008

    Aurora, Colorado

  • Investigational Site Number 8400010

    New Haven, Connecticut

  • Investigational Site Number 8400004

    Atlanta, Georgia

  • Investigational Site Number 8400007

    Chicago, Illinois

  • Investigational Site Number 8400014

    Iowa City, Iowa

  • Investigational Site Number 8400003

    Kansas City, Kansas

  • Investigational Site Number 8400021

    Baltimore, Maryland

  • Investigational Site Number 8400016

    Boston, Massachusetts

  • Investigational Site Number 8400020

    Rochester, Minnesota

  • Investigational Site Number 8400027

    Kansas City, Missouri

  • Investigational Site Number 8400011

    Philadelphia, Pennsylvania

  • Investigational Site Number 8400015

    San Antonio, Texas

  • Investigational Site Number 8400019

    Morgantown, West Virginia

  • Investigational Site Number 8400005

    Madison, Wisconsin

  • Investigational Site Number 8400006

    Milwaukee, Wisconsin

  • Investigational Site Number 0320001

    Buenos Aires, Argentina

  • Investigational Site Number 0320003

    Santa Fe, Argentina

  • Investigational Site Number 0360002

    Herston, Australia

  • Investigational Site Number 0360003

    Nedlands, Australia

  • Investigational Site Number 0360001

    Westmead, Australia

  • Investigational Site Number 0400001

    Graz, Austria

  • Investigational Site Number 0400004

    Vienna, Austria

  • Investigational Site Number 0560001

    Brussels, Belgium

  • Investigational Site Number 0560002

    Leuven, Belgium

  • Investigational Site Number 1240002

    Edmonton, Canada

  • Investigational Site Number 1240003

    Montreal, Canada

  • Investigational Site Number 1240001

    Toronto, Canada

  • Investigational Site Number 1560005

    Beijing, China

  • Investigational Site Number 1560004

    Chengdu, China

  • Investigational Site Number 1560009

    Guangzhou, China

  • Investigational Site Number 1560006

    Hangzhou, China

  • Investigational Site Number 1560002

    Hefei, China

  • Investigational Site Number 1560007

    Nanjing, China

  • Investigational Site Number 1560008

    Nanjing, China

  • Investigational Site Number 1560001

    Shanghai, China

  • Investigational Site Number 1560003

    Shenyang, China

  • Investigational Site Number 2030001

    Prague, Czechia

Showing 40 of 95 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.